Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 344

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1B
Chunk 344
---
 an officer of the Company, 1,643,837 shares of the Company’s common stock at a purchase price per share of $1.825.
    In addition, in a concurrent private placement, the Company also issued to the purchasers in the August 2024 Offering unregistered
    warrants to purchase 1,643,837 shares of the Company’s common stock (the “August 2024 Warrants”). The August 2024
    Warrants are immediately exercisable at an exercise price of $1.70 per share and expire five years from the date of issuance. The
    total net proceeds were approximately $2.5 million, after deducting placement agent and other offering expenses in the amount of
    approximately $0.5 million. In September 2024, the Company filed a registration statement to register the resale by the investors
    of the shares of common stock issuable upon exercise of the August 2024 Warrants. The registration statement was declared effective
    on September 20, 2024.

    d.
    On November 22, 2024, the
    Company completed a registered direct offering, pursuant to which the Company sold and issued to certain investors, including an
    officer of the Company, 1,817,017 shares of the Company’s common stock at a purchase price per share of $1.175. In addition,
    in a concurrent private placement, the Company also issued to the purchasers in the November 2024 Offering unregistered warrants
    to purchase 1,817,017 shares of the Company’s common stock (the “November 2024 Warrants”). The November 2024 Warrants
    are immediately exercisable at an exercise price of $1.05 per share and expire five years from the date of issuance. The total net
    proceeds were approximately $1.8 million, after deducting placement agent and other offering expenses in the amount of approximately
    $0.35 million. In December 2024, the Company filed a registration statement to register the resale by the investors of the shares
    of common stock issuable upon exercise of the November 2024 Warrants. The registration statement was declared effective on December
    31, 2024. In addition, in connection with the November 2024 Offering, the Company issued to the placement agent and its designees
    warrants to purchase an aggregate of 124,212 shares of common stock at an exercise price of $1.3125